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Abstract
Background—Haemophilia is a rare disease for which quality of care varies around the world. 
We propose data-driven indicators as surrogate measures for the provision of haemophilia care 
across countries and over time.
Materials and methods—The guiding criteria for selection of possible indicators were ease of 
calculation and direct applicability to a wide range of countries with basic data collection 
capacities. General population epidemiological data and haemophilia A population data from the 
World Federation of Hemophilia (WFH) Annual Global Survey (AGS) for the years 2013 and 
2010 in a sample of 10 countries were used for this pilot exercise.
Results—Three indicators were identified: (i) the percentage difference between the observed 
and the expected haemophilia A incidence, which would be close to null when all of the people 
with haemophilia A (PWHA) theoretically expected in a country would be known and reported to 
the AGS; (ii) the percentage of the total number of PWHA with severe disease; and (iii) the ratio 
of adults to children among PWHA standardized to the ratio of adults to children for males in the 
general population, which would be close to one if the survival of PWHA is equal to that of the 
general population. Country-specific values have been calculated for the 10 countries.
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Conclusions—We have identified and evaluated three promising indicators of quality of care in 
haemophilia. Further evaluation on a wider set of data from the AGS will be needed to confirm 
their value and further explore their measurement properties.
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Background
Haemophilia is a rare genetic disease that results from mutations in the genes that code for 
proteins necessary for normal blood clotting, called coagulation factors. There is a wide 
variation in the reported prevalence of haemophilia across countries [1–4]. Such variation 
might be partly rooted in genetic causes, but it is likely that variability in the capacity for 
prompt and accurate diagnosis and for the provision of life-saving care [5–7], and the 
economic capacity of countries or individual citizens to afford treatment [8,9] play an 
important role.
As with many other chronic, rare diseases, haemophilia care is heavily dependent on the 
availability of costly resources [10] and a structured multi-professional care model [11–16] 
that is not provided homogeneously everywhere. Many patients are not identified and are 
untreated [9]. A few years ago, an estimate of the underserved haemophilia population was 
proposed at 80% of the total estimated number of haemophilia patients [16]. This number, 
though proposed as the gap to fill, was never formally assessed. The number likely reflected 
the current estimates of poverty rates. The earliest articles in Haemophilia that discussed the 
80% number were Jones [17] and Jones and Robillard [18]. Jones [17] mentions that 80% of 
people with haemophilia A have no access to factor VIII therapy. Jones and Robillard [18] 
mention ‘in the 1990s it was estimated that 80% of the worldwide haemophilia population 
received little or no care, but no data were provided supporting this estimate’.
The World Federation of Hemophilia (WFH), an international not-for-profit organization, 
was established in 1963, as a global network of national member organizations (NMO, 
currently 134) of patients recognized from the World Health Organization. Each year since 
1998 the WFH distributes the AGS questionnaire [19] to all of its NMOs. NMO staff 
members complete the survey (often in collaboration with clinicians and health ministries) 
by providing aggregate demographic, clinical and treatment data on people with bleeding 
disorders in their country. The Data and Demographics Committee (DDC) of the WFH, 
including epidemiologists, haematologists, academic researchers, data collectors and patient 
leaders, provides oversight of the data collection and insight into the interpretation and 
presentation of the AGS data.
With the growing interest in value-based healthcare where expenditure is linked to patient-
centred outcome measures, and a concurrent reduction in available resources, it is relevant to 
identify and propose indicators allowing comparison of the provision of care to haemophilia 
patients, both across countries and within each country over time, with the ultimate goal of 
increasing access to care. The purpose of this paper is to describe the logical process 
followed to identify three indicators designed to provide metrics based on data collected for 
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the AGS that can be used to assess (i) the completeness of identification of people with 
haemophilia (PWH) in a country, (ii) the capacity of a country to correctly classify the 
severity of PWH, and (iii) a measure of survival of PWH in a country.
Materials and methods
Due to differences in the epidemiology of haemophilia A and B, we based our proposed 
measures on haemophilia A, which is the most common of the haemophilias. For the 
analyses presented in this paper, we used data from the AGS on the total number of persons 
with haemophilia A (PWHA), the number of PWHA with severe disease and the number of 
PWHA by age group for the years 2013 (last available) and 2010 (most remote year since 
the last major change in the data collection process).
To provide examples of the calculation and interpretation of the indices, 10 countries were 
selected based on the following criteria: (i) data were provided in the AGS consistently over 
time; (ii) data were relatively complete; and (iii) the countries represented different 
geographical and economic sectors of the world. For each country, demographic data on the 
general population including the total number of males and the number of males by age 
group were obtained from the United States Census Bureau International Database, which 
collates data from national sources. All proposed indicators are percentages or ratios and, 
therefore, they are dimensionless.
Indicators: detailed description of the metrics and calculations
Indicator 1 Percentage difference between the observed and expected 
haemophilia A incidence—Ideally, this indicator would be calculated by comparing the 
observed incidence in a country to the expected (true) incidence of haemophilia, which is 
constant across all countries due to the genetic nature of haemophilia. However, the 
incidence of haemophilia is impossible to measure, primarily due to: (i) the lag between 
birth and diagnosis of haemophilia; (ii) the extreme variability in age of diagnosis for PWH 
with milder disease; and (iii) a further lag in reporting of new cases to a disease registry. 
Therefore, we used the prevalence of haemophilia A in 5–18-year-olds (the earliest age band 
in the AGS allowing sufficient time for diagnosis) as an estimate of the observed incidence. 
This has been verified in population-based studies of haemophilia occurrence, from which 
the value of expected (true) haemophilia A incidence (15.3/100 000 males) was also derived 
[20]. The indicator is calculated for each country using the following equation:
where O is the observed haemophilia A incidence (number of patients with haemophilia A 
in the age group 5–18), and E is the expected haemophilia A incidence (as cases × 100 000 
males).
If a country has identified every case expected, the percentage difference will be 0. If a 
country has identified less than the expected number of patients the indicator will have a 
negative sign. Some of the possible interpretations for a negative value for this indicator are: 
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suboptimal diagnosis of haemophilia, or diagnostic service not offered to the entire 
population at risk; incomplete coverage of the haemophilia care network in the country; 
incomplete capture of cases into the source used to provide data for the AGS. An increase in 
the percentage over time (i.e. a progressive smaller negative number) would indicate an 
improvement in the capacity for complete diagnosis or provision of care. It is also possible 
that the indicator may be greater than zero, i.e. more patients than expected are observed. 
The most likely explanation for this case would be a high number of mild haemophilia 
patients identified.
Indicator 2. The percentage of the total number of PWHA with severe disease
—This indicator is calculated by dividing the number of patients with severe haemophilia A 
by the number of total patients with haemophilia A, multiplied by 100, using the following 
equation:
where S is the number of PWHA with severe haemophilia and T is the total number of 
PWHA.
Usually, severe haemophilia patients are more easily identified. The indicator will be higher 
when fewer mild and moderate than severe patients are identified and registered (e.g. 50%). 
The values will be lower (e.g. 50% vs. 20%), when more mild and moderate than severe 
patients are identified and contribute to the total number of patients. This indicator is 
expected to be associated with the ‘maturity’ of the health care system in a country or 
region. Interpretation may also vary depending on a combination of indicators. For example, 
if the percentage difference of observed from expected PWHA is small, a high percentage of 
severe to total may indicate that the system has recently improved its capacity to reach most 
of the expected patients in the catchment area, but still needs to improve diagnosis of milder 
patients. If instead, the percentage difference of observed from expected PWHA is high, but 
the ratio of severe to non-severe is appropriate, the case is more likely that a good diagnostic 
service has been in place for long enough to properly identify patients in some centres/areas 
of the country, but it has not been extended to the entire country. A decrease in the 
percentage of PWHA with severe disease over time would indicate an improvement in the 
provision of care. A potential confounder for this indicator is represented by suboptimal 
laboratory performance and consequent misclassification of patients, which could affect the 
ratio in either direction.
Indicator 3. The ratio of adults to children among PWHA standardized to the 
ratio of adults to children for males in the general population—The ratio of 
adults to children in haemophilia A is normalized to the ratio of adults to children in the 
male population.
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where PWHA19–44 is the number of people with haemophilia A in the 19–44 age group, 
PWHA5–13 is the number of people with haemophilia A in the 5–13 age group, POP19–44 is 
the number of males in the general population in the 19–44 age group and POP5–13 is the 
number of males in the general population in the 5–13 age group.
The general assumption behind this indicator is that, in the presence of appropriate provision 
of care, the life expectancy in haemophilia should be similar to that of the general 
population. Therefore, when this indicator has a lower than expected number of patients in 
older age bands (a ratio lower than 1), we could hypothesize that either fewer individuals are 
retained in the system as they grow older (e.g. insufficient capacity of the system to care for 
older PWHA), or a lower than expected survival applies to that country (e.g. excess 
mortality). An increase in the ratio over time would indicate an improvement in the 
provision of care. The ratio can be higher than 1, pointing to a survival advantage for 
PWHA, which might be difficult to interpret. Possible explanations would be a differential 
emigration of healthy adults from the country (e.g. healthy adult males being able to leave 
the country more than adult PWHA), mild PWHA being identified by education and 
outreach programmes, or simply different upper limits for categorizing PWHA.
Extreme caution must be used when interpreting these indicators, particularly until a larger 
number of countries are evaluated.
Results
The following 10 countries were selected for the present exercise: Australia, Canada, 
Georgia, Ireland, Republic of Korea, Poland, South Africa, Turkey, UK and USA.
The source data for the general population of the 10 countries by age band (Table 1) and 
corresponding data for the haemophilia population from the AGS (Table 2) have then been 
used to calculate the three indicators. The theoretical incidence of haemophilia A was 
estimated as reported in methods.
Percentage difference of observed from expected incidence of haemophilia A
Percentage difference of observed from expected incidence of haemophilia A in the 10 
countries considered in this pilot exercise are shown in Table 3. Estimates ranged from 
54.2% less in South Africa to 111.1% more than expected incidence of haemophilia A in 
Ireland. Georgia and USA had an observed incidence within 3% of the expected.
Percentage of PWHA with severe haemophilia
Percentage of PWHA with severe haemophilia is shown in Table 4. Results ranged from 
23% in the UK to 70% in the Republic of Korea. The mean and median values for the 11 
countries were 41% and 34% respectively.
Standardized ratios of adult to children PWHA to the ratios of adult to children in the 
general population
Standardized ratios of adult to children PWHA to the ratios of adult to children in the 
general population are shown in Table 5. The ratios ranged from 0.56 in USA to 1.58 in 
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Poland. The ratios average was 0.82; the Republic of Korea and South Africa had ratios very 
close to 1.0.
Table 6 reports the same indicators calculated for 2010, presented side by side with the 
values for 2013 taken from Tables 3–5, and explores the responsiveness of the indicators 
over time.
Discussion
We have identified three indicators describing characteristics of the haemophilia A 
population of a country which should reflect the impact of haemophilia care. We have pilot-
tested the proposed indicators on epidemiologic data from a defined set of countries that 
provide complete and consistent data to the AGS, and we have proposed some basic 
guidance for the interpretation of a range of possible values of the indicators.
The broader scope of this pilot exercise is to propose objective measures reflective of the 
provision of haemophilia care. The proposed indicators can be calculated directly from the 
AGS data and allow comparisons over time within the same country and cross-sectional 
comparisons among different countries. These indicators may represent ‘objective metrics to 
assess the impact of advocacy on the provision of care’, a goal identified as a valuable 
objective by the Medical Advisory Board of WFH. Moreover, the DDC recognized the value 
of the indicators as metrics to be used to verify the internal consistency of the AGS data. 
Finally, these indicators may inform health care development and support health care 
planning and decision-making.
The strengths and limitations of this approach are primarily determined by the quality and 
completeness of the data available in each country to compile the AGS questionnaire. Each 
WFH Report on the Annual Global Survey includes a discussion and list of caveats 
regarding the published data (see, e.g. pages 1–2 of the 2014 report, [21]). All of those 
issues apply to any use of the AGS data such as in this exercise.
The strengths of the indicators are that they rely on relatively basic data about the 
haemophilia population in each country, which in many instances will be readily available. 
A major limitation is that incompleteness of the available data can lead to incorrect 
conclusions about the level of care provision in the country. Therefore, it will be important 
that any interpretation of the indicators be tempered by knowledge of the capacity of each 
country to collect complete data.
For the sake of simplicity, we have decided to focus on haemophilia A only. Whereas the 
same analysis is feasible for haemophilia A and B, either separately or pooled, the former 
would have doubled the complexity of the exercise, and the latter would have increased the 
variability of the indicators, due to the different relative proportion of mild, moderate and 
severe persons with haemophilia B as compared to haemophilia A.
Two future improvements to the percentage difference between observed and expected 
haemophilia A incidence, can be collecting and analysing age bands broken down by 
severity and using Genome-Wide Association Studies [22] or registry data from countries 
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with characteristics similar to the ones being assessed to estimate the true incidence of 
haemophilia. The value we have chosen is much lower than the incidence of haemophilia A 
observed in the UK, Australia, Canada and Ireland (+52.7%, +38.5%, +62.8% and 111.1%; 
Table 3), meaning that many more people than our theoretical benchmark are de facto 
diagnosed in those countries, possibly explained by higher number of mild and/or carriers 
diagnoses. The USA, Turkey and Georgia appear close to the theoretical incidence, while the 
Republic of Korea, Poland and South Africa present a gap ranging from −33.1% to −54.2%. 
We propose that after careful observation for a few years of the incidence observed over time 
in a group of sentinel countries, WFH would reassess which is the proper benchmark 
incidence to consider.
The percentage of severe haemophilia patients as percentage of total patients was lowest in 
UK (23%), Australia (34%) and Canada (29%; Table 4). Georgia presents a similar value, 
but a lower value of Indicator 1 (close to 0). We can anticipate for Georgia an increase in 
Indicator 1 and a decrease in Indicator 2 by expansion of a mature health care system to a 
larger population. In Poland and South Africa, the percentage of severe PWHA is around 
50%, while there is a large negative difference between observed and expected (Table 3). A 
possible interpretation is that not all of the haemophilia population is reached, and those that 
are identified are more likely to have severe disease. Enhancing the diagnostic capacity in 
Poland and South Africa might improve both Indicators 1 and 2 (more patients and/or more 
mild are diagnosed), or improve Indicator 1 and temporarily worsen Indicator 2 (a larger 
number of severe PWHA, but not mild ones, diagnosed from a broader population base). 
Different attitudes toward genetic counselling and prenatal decision-making might also 
impact this indicator.
The standardized ratio of adult to children PWHA is the most sensitive to random variation 
in the AGS data, but is expected to be more robust than a similar indicator previously 
proposed by Evatt and Robillard [16], for it is normalized to the normal population. The 
Republic of Korea and South Africa have values closest to the theoretical value of 1. There 
is a lower than expected representation of older ages in many countries (UK, Australia, 
Ireland, Georgia, Turkey, Canada and USA). This may be the consequence of the high rate 
of blood-borne infections and consequent transient higher mortality and lower life 
expectancy in recent years in countries in which concentrates were largely available during 
the HIV/HCV epidemics. The lowest ratios are observed in USA and Ireland. However, 
Indicator 1 is very different between the two countries (higher in Ireland), and so is Indicator 
2 (higher in USA), suggesting that different explanations have to be sought (e.g. immigration 
of young PWHA in Ireland), and stressing the importance of considering simultaneously the 
three indicators.
The overall performance of the proposed indicators over time (Table 6) shows an overall 
trend for the number to become more positive, but also some significant variability for all 
the three indicators, which makes is difficult and very likely not yet opportune attempting to 
provide guidance for interpretation.
In essence, we are suggesting a change in perspective, from pure ‘advocacy’ (the 80% 
statement), to ascertainment of the percentage (or number) of patients with haemophilia that 
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may receive ‘adequate care’, to be compared across countries and over time. We say ‘may’, 
because diagnosis and registration do not suffice, adequacy of care also requires availability 
of factor concentrates. However, one can foresee that the indicators we are proposing, 
coupled with metrics derived from the units of factor concentrates used in a country, would 
provide a more efficient indicator than the traditional unit per capita measure. The task 
accomplished and discussed with the current paper is equivalent to creating a scaffold or 
reasonably robust numbers that can reflect quality of care, without going into discussing 
‘adequacy of treatment’ in terms of units per capita or per patient.
Indeed, an interesting set of criticisms was raised in preliminary discussion and presentation 
of this paper to relevant stakeholders. Essentially, it is suggested that the indicators are 
sensitive to well-known phenomena like overestimation of proportion of PWHA as 
consequence of selective immigration of PWHA; underestimation of patients identified 
(diagnosed) and (well) treated in the developing world; and (systematic) underestimation of 
the number of patients affected by mild haemophilia in the developing world. As a 
consequence, the number of IU/capita estimated in the presence of the suggested over- or 
under-estimations will be as unreliable as the proposed indicators. Although one cannot 
deny the value units per capita has had on improving the care provided to haemophilia 
patients. Indeed, we are well aware that the proposed indicators (like IU/capita) are as good 
as the data they are calculated on. However, the AGS data are the best data that we have on a 
broad set of countries, and until they are benchmarked against better (and hopefully 
individual patient level) data from the same countries/areas, AGS data remain as the 
mainstay for planning and assessing haemophilia care and advocacy efforts. Any 
discrepancy (in plus or minus from the average value of each of the indicator) can be 
difficult to explain, but is notwithstanding pointing to some specific phenomenon worth 
investigation.
In this paper, we have provided a detailed explanation of the rationale for choosing the 
indicators, the formulas used to calculate them and examples of the indicators as calculated 
for a sample set of countries. It is not our aim to make any specific judgement on the specific 
countries involved or on the absolute appropriateness of the reference value proposed for the 
expected number of people with haemophilia [18]. We offer this as a proof-of-concept for 
one possible approach to a standardized assessment of some aspects of the provision of care 
to PWHA. The indicators here proposed need to be calculated on the AGS data for a few 
years, and interpreted until shown to reproducibly and meaningfully measure the quality of 
care for haemophilia. This would ideally lead to the ultimate goal to produce a standardized 
index or a set of metrics to complement, substantiate and ultimately replace the historical 
80% definition.
In summary, we are confident that the proposed indicators were found to have some 
desirable properties, like discrimination (capacity to differentiate different levels in different 
settings) and responsiveness (capacity to measure changes over time) globally or within a set 
of countries. Face value relative to provision of care and widespread availability of the data 
needed for their calculation would be welcome additional characteristics. Finally, caution 
must be used when interpreting these indicators, particularly until a larger number of 
countries are evaluated.
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Table 3
Percentage difference between the observed and the expected incidence of haemophilia A in 10 countries, 
2013 (Indicator 1).





Korea, Republic of 9.29 −39.3
Poland 10.23 −33.1




This indicator assumes an expected incidence of people with haemophilia A in the population of 15.3 per 100 000 males, estimated from Soucie et 
al. [20].
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Table 4
Severe haemophilia A patients as percentage of total haemophilia A patients in 10 countries, 2013 (Indicator 
2).
Country Total haemophilia A Severe haemophilia A % severe haemophilia A
Australia 2071 713 34
Canada 3006 869 29
Georgia 232 64 28
Ireland 575 197 34
Korea, Republic of 1602 1116 70
Poland 2280 1216 53
South Africa 1741 1045 60
Turkey 4369 1476 34
UK 5651 1291 23
USA 12 957 6841 53
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Table 5
Ratio of adult to children haemophilia A cases standardized to the ratio of adult to children in the general 
population of 10 countries, 2013 (Indicator 3).
Ratio (19–44)/(5–13)
Rate ratio PWHA/Gen popPWHA General population
Australia 2.788 3.396 0.82
Canada 2.947 3.668 0.80
Georgia 2.775 3.540 0.78
Ireland 2.255 3.127 0.72
Korea, Republic of 4.179 4.298 0.97
Poland 7.112 4.509 1.58
South Africa 2.617 2.625 1.00
Turkey 2.070 2.573 0.80
UK 2.916 3.417 0.85
USA 1.652 2.945 0.56
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